Next Article in Journal
Access to Cancer Care in Northwestern Ontario—A Population-Based Study Using Administrative Data
Previous Article in Journal
Prognosis and Clinicopathologic Features in Patients with Gastric Stump Cancer after Curative Surgery
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Does the Time from Diagnostic Biopsy to Neoadjuvant Chemotherapy Affect the Rate of Pathologic Complete Response in Stages I–III Breast Cancer?

1
BC Cancer, Fraser Valley Cancer Centre, Surrey, BC, Canada
2
University of British Columbia, Vancouver, BC, Canada
3
Yale School of Public Health, New Haven, CT, USA
4
BC Cancer, Vancouver Centre, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(3), 265-270; https://doi.org/10.3747/co.27.5907
Submission received: 3 March 2020 / Revised: 5 April 2020 / Accepted: 7 May 2020 / Published: 1 June 2020

Abstract

Background: Studies in the adjuvant setting suggest that the timing of breast cancer diagnosis, surgery, and chemotherapy might affect outcomes. In the neoadjuvant setting, data exploring whether expeditious neoadjuvant chemotherapy (nac) after diagnosis improves the rate of pathologic complete response (pcr) in breast cancer are limited. Methods: Patients who received nac and completed treatment between May 2012 and December 2018 were identified from a prospectively collected database at BC Cancer. Time from diagnosis to start of nac was calculated. Patients were grouped into those who did and did not experience a pcr, and those who started nac within 28 days or after 28 days [time to nac (ttn)]. The association between pcr and ttn was tested using logistic regression. Results: In the time period studied, 482 patients who received nac were identified. After exclusions, 421 patients met the eligibility criteria. Median time from biopsy to chemotherapy was 33 days (range: 7–140 days). In 149 patients (35.4%), nac was received within 28 days of diagnosis (range: 7–28 days); in 272 patients (64.6%), it was received after more than 28 days (range: 29–140 days). The overall pcr rate was 31.8%. A trend toward a higher pcr rate, although not statistically significant, was observed in the group that initiated chemotherapy within 28 days (34.2% vs. 30.5%, p = 0.43). In the logistic regression model, rates of pcr were associated with receptor status, but not age, stage, or ttn. Conclusions: In the neoadjuvant setting, we observed no difference in the rate of pcr in patients who started nac within 28 days or after 28 days.
Keywords: breast cancer; neoadjuvant chemotherapy; pathologic complete response; time to treatment breast cancer; neoadjuvant chemotherapy; pathologic complete response; time to treatment

Share and Cite

MDPI and ACS Style

Le, D.; Eslami, M.; Li, H.; Hajjaj, O.; Chia, S.; Simmons, C. Does the Time from Diagnostic Biopsy to Neoadjuvant Chemotherapy Affect the Rate of Pathologic Complete Response in Stages I–III Breast Cancer? Curr. Oncol. 2020, 27, 265-270. https://doi.org/10.3747/co.27.5907

AMA Style

Le D, Eslami M, Li H, Hajjaj O, Chia S, Simmons C. Does the Time from Diagnostic Biopsy to Neoadjuvant Chemotherapy Affect the Rate of Pathologic Complete Response in Stages I–III Breast Cancer? Current Oncology. 2020; 27(3):265-270. https://doi.org/10.3747/co.27.5907

Chicago/Turabian Style

Le, D., M. Eslami, H. Li, O. Hajjaj, S. Chia, and C. Simmons. 2020. "Does the Time from Diagnostic Biopsy to Neoadjuvant Chemotherapy Affect the Rate of Pathologic Complete Response in Stages I–III Breast Cancer?" Current Oncology 27, no. 3: 265-270. https://doi.org/10.3747/co.27.5907

APA Style

Le, D., Eslami, M., Li, H., Hajjaj, O., Chia, S., & Simmons, C. (2020). Does the Time from Diagnostic Biopsy to Neoadjuvant Chemotherapy Affect the Rate of Pathologic Complete Response in Stages I–III Breast Cancer? Current Oncology, 27(3), 265-270. https://doi.org/10.3747/co.27.5907

Article Metrics

Back to TopTop